Session Type: 1,5-hour Oral Session
Session Title: 1,5-hour Oral Session
Authors(s): D. Nieves, S. Osborne, N. Ashouri, J. Singh, A. Arrieta
Authors Affiliations(s): CHOC Children's Hospital, United States
Background:
Pneumococcus is responsible for more than 3 million deaths worldwide in children < 5 years, 13-valent pneumococcal conjugate vaccine (PCV-13) has reduced invasive pneumococcal disease (IPD), yet other serotypes have emerged. PCV-15 (serotypes in PCV-13 + 22F and 33F) and PCV-20 (serotypes in PCV-13 + 8, 10A, 11A, 12F, 15B, 22F, and 33F) are being studied.
Methods:Pospectively collected data on pediatric cases of IPD from 2010 to 2020 including demographics, clinical presentation, serotype information and PCV-13 immunization status.
Results:We identified 211 IPD (92 female; 145 White; 181 bacteremia; 27 meningitis; 85 pneumonia including 28 empyema); 64 (30%) IPD occurred in PCV13 fully immunized patients, 21/64(33%) had PCV-13 serotype IPD [19A(12), 3(6), 19F(2), and 14(1)] (16 pneumonia) while 39/64 (61%) were Non-PCV-13 serotypes (13 pneumonias); 7 (18%) and 16 (41%) are included in PCV-15 and PCV-20 respectively. Another 56 (27%) cases occurred in partially PCV-13 immunized children; 14/56 (25%) werePCV-13 serotype [3(9) and 19A(5)], 10 with pneumonia; 36/56 (64%) were Non-PCV-13 serotypes including 11 with pneumonia; 8 (22%) and 22 (61%) are included in PCV-15 and PCV-20 respectively. The other 91 (43%) cases occurred in PCV-13 non-immunized patients; 32/91(35%) had PCV13 serotype [7F(12), 19A(7), 3(5), 6A(3),19F(3), 5(1) and 23F(1)], 16 with pneumonia, while 40 (44%) were Non-PCV-13 serotypes (9 pneumonia); 7 (18%) and 17 (43%) are included in PCV-15 and PCV-20 respectively. Among the 33 cases of pneumonia due to non-PCV-13 serotype, 9 (27%) and 16 (48%) serotypes are included in PCV-15 and PCV-20 respectively. Twenty-five cases of meningitis were identified, 7(28%) were PCV-13 serotypes (6 patients no PCV-13 and 1 with single dose PCV-13; 18(72%) were non-PCV-13 serotypes; 4 (22%) and 11 (61%) are included in PCV-15 and PCV-20 respectively. Serotype was not identified In 29 (13.7%) IPD cases. Annual rise of total IPD mirrors the rise in non-PCV13 serotypes (figure 1). Nearly half of the nonPCV-13 serotypes were PCV-15 or PCV-20 serotypes (figure 2).
Conclusions:Improved PCV vaccines should further reduce burden of serious IPD in children. In our cohort, PCV-15 and PCV-20 could have prevented 22 and 55 additional cases respectively including 33 pneumonia and 18 meningitis cases.
Keyword(s): invasive pneumococcal disease, pediatric immunization, serious bacterial illnessSession Type: 1,5-hour Oral Session
Session Title: 1,5-hour Oral Session
Authors(s): D. Nieves, S. Osborne, N. Ashouri, J. Singh, A. Arrieta
Authors Affiliations(s): CHOC Children's Hospital, United States
Background:
Pneumococcus is responsible for more than 3 million deaths worldwide in children < 5 years, 13-valent pneumococcal conjugate vaccine (PCV-13) has reduced invasive pneumococcal disease (IPD), yet other serotypes have emerged. PCV-15 (serotypes in PCV-13 + 22F and 33F) and PCV-20 (serotypes in PCV-13 + 8, 10A, 11A, 12F, 15B, 22F, and 33F) are being studied.
Methods:Pospectively collected data on pediatric cases of IPD from 2010 to 2020 including demographics, clinical presentation, serotype information and PCV-13 immunization status.
Results:We identified 211 IPD (92 female; 145 White; 181 bacteremia; 27 meningitis; 85 pneumonia including 28 empyema); 64 (30%) IPD occurred in PCV13 fully immunized patients, 21/64(33%) had PCV-13 serotype IPD [19A(12), 3(6), 19F(2), and 14(1)] (16 pneumonia) while 39/64 (61%) were Non-PCV-13 serotypes (13 pneumonias); 7 (18%) and 16 (41%) are included in PCV-15 and PCV-20 respectively. Another 56 (27%) cases occurred in partially PCV-13 immunized children; 14/56 (25%) werePCV-13 serotype [3(9) and 19A(5)], 10 with pneumonia; 36/56 (64%) were Non-PCV-13 serotypes including 11 with pneumonia; 8 (22%) and 22 (61%) are included in PCV-15 and PCV-20 respectively. The other 91 (43%) cases occurred in PCV-13 non-immunized patients; 32/91(35%) had PCV13 serotype [7F(12), 19A(7), 3(5), 6A(3),19F(3), 5(1) and 23F(1)], 16 with pneumonia, while 40 (44%) were Non-PCV-13 serotypes (9 pneumonia); 7 (18%) and 17 (43%) are included in PCV-15 and PCV-20 respectively. Among the 33 cases of pneumonia due to non-PCV-13 serotype, 9 (27%) and 16 (48%) serotypes are included in PCV-15 and PCV-20 respectively. Twenty-five cases of meningitis were identified, 7(28%) were PCV-13 serotypes (6 patients no PCV-13 and 1 with single dose PCV-13; 18(72%) were non-PCV-13 serotypes; 4 (22%) and 11 (61%) are included in PCV-15 and PCV-20 respectively. Serotype was not identified In 29 (13.7%) IPD cases. Annual rise of total IPD mirrors the rise in non-PCV13 serotypes (figure 1). Nearly half of the nonPCV-13 serotypes were PCV-15 or PCV-20 serotypes (figure 2).
Conclusions:Improved PCV vaccines should further reduce burden of serious IPD in children. In our cohort, PCV-15 and PCV-20 could have prevented 22 and 55 additional cases respectively including 33 pneumonia and 18 meningitis cases.
Keyword(s): invasive pneumococcal disease, pediatric immunization, serious bacterial illness
Session Type: 1,5-hour Oral Session
Session Title: 1,5-hour Oral Session
Authors(s): D. Nieves, S. Osborne, N. Ashouri, J. Singh, A. Arrieta
Authors Affiliations(s): CHOC Children's Hospital, United States
Background:
Pneumococcus is responsible for more than 3 million deaths worldwide in children < 5 years, 13-valent pneumococcal conjugate vaccine (PCV-13) has reduced invasive pneumococcal disease (IPD), yet other serotypes have emerged. PCV-15 (serotypes in PCV-13 + 22F and 33F) and PCV-20 (serotypes in PCV-13 + 8, 10A, 11A, 12F, 15B, 22F, and 33F) are being studied.
Methods:Pospectively collected data on pediatric cases of IPD from 2010 to 2020 including demographics, clinical presentation, serotype information and PCV-13 immunization status.
Results:We identified 211 IPD (92 female; 145 White; 181 bacteremia; 27 meningitis; 85 pneumonia including 28 empyema); 64 (30%) IPD occurred in PCV13 fully immunized patients, 21/64(33%) had PCV-13 serotype IPD [19A(12), 3(6), 19F(2), and 14(1)] (16 pneumonia) while 39/64 (61%) were Non-PCV-13 serotypes (13 pneumonias); 7 (18%) and 16 (41%) are included in PCV-15 and PCV-20 respectively. Another 56 (27%) cases occurred in partially PCV-13 immunized children; 14/56 (25%) werePCV-13 serotype [3(9) and 19A(5)], 10 with pneumonia; 36/56 (64%) were Non-PCV-13 serotypes including 11 with pneumonia; 8 (22%) and 22 (61%) are included in PCV-15 and PCV-20 respectively. The other 91 (43%) cases occurred in PCV-13 non-immunized patients; 32/91(35%) had PCV13 serotype [7F(12), 19A(7), 3(5), 6A(3),19F(3), 5(1) and 23F(1)], 16 with pneumonia, while 40 (44%) were Non-PCV-13 serotypes (9 pneumonia); 7 (18%) and 17 (43%) are included in PCV-15 and PCV-20 respectively. Among the 33 cases of pneumonia due to non-PCV-13 serotype, 9 (27%) and 16 (48%) serotypes are included in PCV-15 and PCV-20 respectively. Twenty-five cases of meningitis were identified, 7(28%) were PCV-13 serotypes (6 patients no PCV-13 and 1 with single dose PCV-13; 18(72%) were non-PCV-13 serotypes; 4 (22%) and 11 (61%) are included in PCV-15 and PCV-20 respectively. Serotype was not identified In 29 (13.7%) IPD cases. Annual rise of total IPD mirrors the rise in non-PCV13 serotypes (figure 1). Nearly half of the nonPCV-13 serotypes were PCV-15 or PCV-20 serotypes (figure 2).
Conclusions:Improved PCV vaccines should further reduce burden of serious IPD in children. In our cohort, PCV-15 and PCV-20 could have prevented 22 and 55 additional cases respectively including 33 pneumonia and 18 meningitis cases.
Keyword(s): invasive pneumococcal disease, pediatric immunization, serious bacterial illnessSession Type: 1,5-hour Oral Session
Session Title: 1,5-hour Oral Session
Authors(s): D. Nieves, S. Osborne, N. Ashouri, J. Singh, A. Arrieta
Authors Affiliations(s): CHOC Children's Hospital, United States
Background:
Pneumococcus is responsible for more than 3 million deaths worldwide in children < 5 years, 13-valent pneumococcal conjugate vaccine (PCV-13) has reduced invasive pneumococcal disease (IPD), yet other serotypes have emerged. PCV-15 (serotypes in PCV-13 + 22F and 33F) and PCV-20 (serotypes in PCV-13 + 8, 10A, 11A, 12F, 15B, 22F, and 33F) are being studied.
Methods:Pospectively collected data on pediatric cases of IPD from 2010 to 2020 including demographics, clinical presentation, serotype information and PCV-13 immunization status.
Results:We identified 211 IPD (92 female; 145 White; 181 bacteremia; 27 meningitis; 85 pneumonia including 28 empyema); 64 (30%) IPD occurred in PCV13 fully immunized patients, 21/64(33%) had PCV-13 serotype IPD [19A(12), 3(6), 19F(2), and 14(1)] (16 pneumonia) while 39/64 (61%) were Non-PCV-13 serotypes (13 pneumonias); 7 (18%) and 16 (41%) are included in PCV-15 and PCV-20 respectively. Another 56 (27%) cases occurred in partially PCV-13 immunized children; 14/56 (25%) werePCV-13 serotype [3(9) and 19A(5)], 10 with pneumonia; 36/56 (64%) were Non-PCV-13 serotypes including 11 with pneumonia; 8 (22%) and 22 (61%) are included in PCV-15 and PCV-20 respectively. The other 91 (43%) cases occurred in PCV-13 non-immunized patients; 32/91(35%) had PCV13 serotype [7F(12), 19A(7), 3(5), 6A(3),19F(3), 5(1) and 23F(1)], 16 with pneumonia, while 40 (44%) were Non-PCV-13 serotypes (9 pneumonia); 7 (18%) and 17 (43%) are included in PCV-15 and PCV-20 respectively. Among the 33 cases of pneumonia due to non-PCV-13 serotype, 9 (27%) and 16 (48%) serotypes are included in PCV-15 and PCV-20 respectively. Twenty-five cases of meningitis were identified, 7(28%) were PCV-13 serotypes (6 patients no PCV-13 and 1 with single dose PCV-13; 18(72%) were non-PCV-13 serotypes; 4 (22%) and 11 (61%) are included in PCV-15 and PCV-20 respectively. Serotype was not identified In 29 (13.7%) IPD cases. Annual rise of total IPD mirrors the rise in non-PCV13 serotypes (figure 1). Nearly half of the nonPCV-13 serotypes were PCV-15 or PCV-20 serotypes (figure 2).
Conclusions:Improved PCV vaccines should further reduce burden of serious IPD in children. In our cohort, PCV-15 and PCV-20 could have prevented 22 and 55 additional cases respectively including 33 pneumonia and 18 meningitis cases.
Keyword(s): invasive pneumococcal disease, pediatric immunization, serious bacterial illness